Top Stories

Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies

A company developing a drug to address the growing need for safe ways to condition patients receiving cell and gene therapies is partnering with a firm developing single letter-level gene editing to investigate ways to apply its approach in patients with blood disorders. Cambridge, Massachusetts-based Magenta Therapeutics and Beam Therapeutics said Monday that they had […]

Top Stories

Presentations at EHA highlight gene therapy approaches to beta-thalassemia, sickle cell disease

Two different gene therapy approaches to treating two blood disorders were the subject of presentations at a hematology meeting Friday, with both showing efficacy. Cambridge, Massachusetts-based bluebird bio said that data from its Phase III study of Zynteglo (betibeglogene autotemcel) – also known as LentiGlobin – in transfusion-dependent beta-thalassemia (TDT) presented at the European Hematology […]


Getting Tested for MTHFR Gene Variants Is All the Rage—But Here’s Why I Don’t Suggest It

Depression. Autism. Breast cancer. Alcoholism. Type 1 diabetes. Heart disease. What do these supposedly have in common? Many alternative health websites like to talk about a supposed link between these conditions and a gene called MTHFR—but there's no indisputable evidence that the link really exists. If you’re unfamiliar with the MTHFR gene, it stands for […]